Skip to content

Insider · CIK 0001611024

David D Chang

ceopresidentofficerdirector

Files at ALLO (Allogene Therapeutics, Inc.). First filing Feb 5, 2025, latest Mar 18, 2025.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $169k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

ALLO: Allogene Therapeutics, Inc.

ALLOOct 9, 2026 · close 1.46

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
42Moderate
ALLOsell 2
Allogene Therapeutics, Inc.
$91k
46,668 shares
-1%+39% from low-40% from high
48Moderate
ALLOsell 5
Allogene Therapeutics, Inc.
$77k
46,003 shares
-1%0% from low-48% from high

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Mar 14, 2025ALLO
Allogene Therapeutics, Inc.
SOpen-market sale
Common Stock
-46,668$1.96$91k5,276,569Mar 18, 2025
Feb 3, 2025ALLO
Allogene Therapeutics, Inc.
SOpen-market sale
Common Stock
-46,003$1.68$77k5,317,237Feb 5, 2025
Jan 24, 2025ALLO
Allogene Therapeutics, Inc.
AGrant or award
Common Stock
+552,174$0.00$05,363,240Jan 28, 2025
Jan 24, 2025ALLO
Allogene Therapeutics, Inc.
AGrant or award
Stock Option (Right to buy)derivative
+1,952,130$0.00$01,952,130Jan 28, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

David D Chang: insider trades and track record | InsiderTell